AAN: Race May Affect Response to Anti-CD20 Therapy for MS, NMOSD

THURSDAY, April 15, 2021 -- For patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) receiving anti-CD20 treatment, B-cell repopulation occurs in more African American than White patients between six and 12 months...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news